Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Breast Ref Set Applicant: Anu Mathew-Meso Scale (2012) Mathew, Anu
Breast Reference Set Applicant: Tuszynski-Temple (2012) Feng, Ziding
Breast Reference Set Applicant: Zangar-PNNL (2012) Feng, Ziding
Breast Reference Set Applicant:- Zangar-Pacific NW Nat'l Laboratory (2012) Feng, Ziding
Breast Reference Set Application: Anu Mathew-Meso Scale (2012) Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic ... Mathew, Anu
Breast Reference Set Application: Chris Li-FHCRC (2014) This application proposes to use Reference Set #1. We request access to serum samples collected at the time of breast biopsy from subjects with IC (n=30) or ... Li, Christopher
Breast Reference Set Application: GeorgeTuszynski-Temple (2012) Feng, Ziding
Breast Reference Set Application: Karen Abbott- University of Arkansas (2013) We are evaluating whether detection of a tumor-specific N-linked glycosylation known as B 1,6 branched N-glycan present on the glycoprotein periostin in breast ... Abbott, Karen
Breast Reference Set Application: Karen Anderson-ASU (2014) In order to increase the predictive value of tumor-specific antibodies for use as immunodiagnostics, our EDRN BDL has developed a novel protein microarray ... Anderson, Karen
Breast Reference Set Application: Pinku Mukherhjee-CanDiag (2014) Mukherhjee, Pinku
Breast Reference Set Application: Pinku Mukherjee-CanDiag (2014) We would like to get all three sets of specimens, however, we are requesting Specimen Set 1 first: 30 subjects with invasive cancer and 30 subjects with benign ... Mukherhjee, Pinku
Breast Reference Set Application: Richard Zangar-PNNL (2012) Our immediate goal is to define a set of biomarkers (composed of circulating plasma proteins) that can be used to distinguish between true and false screens, ... Feng, Ziding
Breast tissue array Chia, David
CLUE Studies: Evaluating Biomarkers of Carcinogenesis Helzlsouer, Kathy
Canary TMA This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict ... Nelson, Peter S
Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients BACKGROUND: Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), and CYFRA 21-1 are the most useful markers for non-small cell lung ... Kulpa, Jan
Chemokine Prostate Cancer Biomarkers STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers ... Macoska, Jill
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. ... Kinsinger, Chris
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC). Kinsinger, Chris
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential ... Liu, Alvin Y.
Clinical Validation of Molecular Signatures of Cervical Neoplasia Unger, Elizabeth R.
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies Chan, Daniel
Clinical validation of an autoantibody test for lung cancer BACKGROUND: Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may ... Boyle, Peter
Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Identification of molecular markers often leads to important clinical applications such as early diagnosis, prognosis, and drug targeting. Lung cancer, the ... Kim, Bumjin
Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers Semmes, John
Colon Reference Set Application: Robert Getzenberg - Johns Hopkins (2008) The goal of this project is to confirm the early validation of CCSA-3 and CCSA-4 as biomarkers for the early detection of adenocarcinoma of the colon and ... Getzenberg, Robert H.
Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008) The proposed study aims to validate the diagnostic value of a panel of serum antibodies for the early detection of colorectal cancer (CRC). We have developed a ... Disis, Mary L
Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008) The goal of this project is to confirm the early validation of CCSA-3 and CCSA-4 as biomarkers for the early detection of adenocarcinoma of the colon and ... Getzenberg, Robert H.
Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006) No Data Received at DMCC Jendoubi, Moncef
Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008) Kim, Nam
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement